FHTX Quote, Financials, Valuation and Earnings

Halozyme Therapeutics, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of -31.34%. Foghorn Therapeutics, Inc.'s return on equity of -- beat Halozyme Therapeutics, Inc.'s return on equity of 91.5%.

Foghorn Therapeutics, Inc. has a consensus price target of $11.44, signalling upside risk potential of 96.3%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $84.50 which suggests that it could grow by 17.3%. Given that Foghorn Therapeutics, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Foghorn Therapeutics, Inc. is more attractive than Halozyme Therapeutics, Inc..

Foghorn Therapeutics, Inc. has a beta of 3.021, which suggesting that the stock is 202.06% more volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.227%.

Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.

Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $451.8M. Foghorn Therapeutics, Inc.'s net income of -$15.8M is higher than Halozyme Therapeutics, Inc.'s net income of -$141.6M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while Halozyme Therapeutics, Inc.'s PE ratio is 28.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 14.53x versus 6.33x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of 34.4%. Foghorn Therapeutics, Inc.'s return on equity of -- beat Eli Lilly & Co.'s return on equity of 104.39%.

Foghorn Therapeutics, Inc. has a consensus price target of $11.44, signalling upside risk potential of 96.3%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,206.07 which suggests that it could grow by 17.87%. Given that Foghorn Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Foghorn Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Foghorn Therapeutics, Inc. has a beta of 3.021, which suggesting that the stock is 202.06% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 45.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 14.53x versus 14.30x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Oramed Pharmaceuticals, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of -382.1%. Foghorn Therapeutics, Inc.'s return on equity of -- beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.

Foghorn Therapeutics, Inc. has a consensus price target of $11.44, signalling upside risk potential of 96.3%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 2.52%. Given that Foghorn Therapeutics, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Foghorn Therapeutics, Inc. is more attractive than Oramed Pharmaceuticals, Inc..

Foghorn Therapeutics, Inc. has a beta of 3.021, which suggesting that the stock is 202.06% more volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.

Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.89% to investors and pays a quarterly dividend of $0.25 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 14.53x versus 65.99x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of 36.91%. Foghorn Therapeutics, Inc.'s return on equity of -- beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Foghorn Therapeutics, Inc. has a consensus price target of $11.44, signalling upside risk potential of 96.3%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $530.70 which suggests that it could grow by 13.09%. Given that Foghorn Therapeutics, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Foghorn Therapeutics, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Foghorn Therapeutics, Inc. has a beta of 3.021, which suggesting that the stock is 202.06% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 30.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 14.53x versus 10.03x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.